Veterinary service and supervision of equine competitions

Because of the growing interest in animal health and welfare in breeding and sport--specially in the horse--the regulation of the German Riding Association (FN) was updated. The result--the LPO 2000--refer more functions to the veterinarian. At first the permanent presence of the vet is necessary, at second he controls the correct, new installed vaccination against influenza-virus. The functions of vet-check, general horse-control and doping are wide up in number and consultation. For this the veterinarian must decree about much experience and good preparation. The organisations of the veterinarians of the countries and the FN work together to develop the knowledge and competence in horse-sport for a better protection.     

Outcome following treatment of vertebral tumors in 20 dogs (1986-1995)

Twenty dogs with histopathologically confirmed primary (n=15) or metastatic (n=5) osteosarcoma (n=14) or fibrosarcoma (n=6) of the vertebral column were treated with surgery (n=4), radiation therapy and chemotherapy (n=6), surgery and chemotherapy (n=2), or surgery, radiation, and chemotherapy (n=8). All dogs died due to their disease; 15 died due to local failure, and five died due to nonvertebral metastasis. Overall median survival time was 135 days, with a range of 15 to 600 days. Of the factors evaluated, only postoperative neurological status had a significant influence on outcome by multivariate analysis. This study supports the overall guarded prognosis for dogs with vertebral neoplasia. Better combinations of surgery, chemotherapy, and radiation therapy remain to be defined for this difficult subset of animal cancer.     

Long-term outcome of horses with a slab fracture of the central or third tarsal bone treated conservatively: 25 cases (1976-1993)

OBJECTIVE: To determine clinical features of horses with a slab fracture of the central or third tarsal bone and to report outcome of horses in which treatment did not include surgery. DESIGN: Retrospective study. ANIMALS: 25 horses (14 Standardbreds, 6 Thoroughbreds, 5 Quarter Horses). PROCEDURE: Medical records of horses with a slab fracture of the central (n = 9) or third (16) tarsal bone were reviewed. Only horses for which treatment consisted of confinement to a stall were included in this study. Clinical features and radiographic findings were recorded and summarized. Outcome was determined for racing breeds by obtaining official lifetime race results. Outcome for Quarter Horses was determined by phone survey of the owners. RESULTS: 16 (64%) horses had a successful outcome. Ten of 14 (71%) Standardbreds and 2 of 6 Thoroughbreds returned to racing and started at least 5 races after injury. Four of 5 Quarter Horses for which follow-up information was available successfully returned to their previous activity. Sex, age, limb affected, or gait was not associated with final outcome. Percentage of racehorses with central tarsal bone fractures that had a successful outcome (2/7) was significantly less than percentage with third tarsal bone fractures that did (10/13). CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that enforced rest without surgical fixation can be an effective therapeutic option for horses with a slab fracture of the central or third tarsal bone, even if athletic function is expected.     

Cuterebra myiasis in a group of red kangaroos (Megaleia rufa), a Bennett's wallaby (Macropus rufogriseus fruticus), and a Gunther's dik dik (Maloqua guentheri smithi).

A group of four red kangaroos (Megaleia rufa), a Bennett's wallaby (Macropus rufogriseus fruticus), and a Gunther's dik dik (Maloqua guentheri smithi) were presented over a 2-mo period with draining lesions over the thorax or on the lateral aspect of a hind leg. Only one animal exhibited more than one lesion. Physical examinations revealed infections with fly larvae. The parasites were manually removed and identified as Cuterebra spp. All of the affected animals survived, with no apparent side effects.     

The effects of morphine on the recovery of horses from halothane anaesthesia

OBJECTIVE: To investigate the effects of peri-operative morphine on the quality and duration of recovery from halothane anaesthesia in horses. STUDY DESIGN: Prospective randomized study. ANIMALS: Twenty-two client owned horses, ASA category I or II. METHODS: Horses undergoing elective surgical procedures were divided into two groups and paired according to procedure, body position during surgery, body mass and breed. Group M+ received morphine by intravenous injection (0.15 mg kg(-1)) before induction of anaesthesia and then by infusion (0.1 mg kg(-1) hour(-1)) during anaesthesia. Group M- received the same anaesthetic agents except that morphine was excluded. At the end of surgery, the horses were placed in a recovery box and allowed to recover without assistance. Recoveries were recorded on videotape, beginning when the anaesthetist left the recovery box, and ending when the horse stood up. Recoveries were assessed from digital video recordings by three observers, unaware of treatment. The time to first movement, attempting and attaining sternal recumbency and standing were recorded. The quality of various aspects of the recovery was assessed to produce a total recovery score; high numerical values indicate poor recoveries. The duration of anaesthesia and the total dose of morphine administered were recorded. RESULTS: The mean morphine dose (95% CI) was 147 (135-160) mg [equivalent to 0.27 (0.25-0.29) mg kg(-1)]. The recovery scores (median, 95% CI) for the M- and M+ groups were 25, 19-41 and 20, 14-26, respectively. Total score increased as duration of anaesthesia increased, independent of treatment. Untreated (M-) horses made more attempts to achieve sternal recumbency: mean number of attempts (95% CI) for M- was 4.5 (2.7-6.2) compared with 2.0 (1.4-2.6) (M+). Untreated horses made more attempts to stand (2.1, 1.6-2.6) compared with the morphine recipients (1.3, 1.1-1.5). Time to standing (in minutes) was significantly (p = 0.0146) longer for the untreated (31.3, 24.3-38.3) compared with treated animals (26.6, 20.9-32.3). The interval between the first movement in recovery to the time at standing was significantly (p < 0.001) longer for M- (14.5, 12.1-16.9 minutes) compared with M+ animals (7.4, 5.0-9.8 minutes). CONCLUSIONS AND CLINICAL RELEVANCE: Recoveries from anaesthesia in the morphine recipients were characterized by fewer attempts to attain sternal recumbency and standing, and a shorter time from the first recovery movement to the time of standing.     

Serological changes observed in horses infected with Anoplocephala perfoliata after treatment with praziquantel and natural reinfection

The serological changes in two groups of horses known to be harbouring Anoplocephala perfoliata were studied; 12 were treated with 1.5 mg/kg praziquantel and 200 microg/kg ivermectin, and 14 were treated with 200 microg/kg ivermectin. Serological and faecal analyses were carried out on each animal at intervals for 758 days. The titres of antibodies specific for A perfoliata decreased from the day of treatment to day 28 in both groups, and continued to decrease in the group treated with praziquantel and ivermectin, with the first significant decrease from the other group at day 121. From day 151 to day 295 the first significant increase in antibody levels in the group treated with both drugs was observed; no A perfoliata eggs were detected in the faeces of these animals until day 295 when five of the 10 were positive.     

Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005)

OBJECTIVE: To determine clinical activity and toxic effects of lomustine when used to treat cats with mast cell tumors (MCTs). DESIGN: Retrospective case series. ANIMALS: 38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage > or = 50 mg/m(2). PROCEDURES: Medical records were reviewed to determine response to treatment and evidence of drug toxicoses. The Kaplan-Meier method was used to estimate remission duration. RESULTS: 26 cats had cutaneous MCTs, 7 had MCTs of the mesenteric lymph nodes, 2 had gastrointestinal tract MCTs, 2 had hepatic MCTs, and 1 had MCTs involving multiple organs. Targeted lomustine dosage was 50 mg/m(2) in 22 cats and 60 mg/m(2) in 16 cats. Median administered dosage of lomustine was 56 mg/m(2) (range, 48 to 65 mg/m(2)), and median number of doses administered was 2 (range, 1 to 12). Seven cats had a complete response and 12 had a partial response, for an overall response rate of 50%. Median response duration was 168 days (range, 25 to 727 days). The most common toxicoses were neutropenia and thrombocytopenia. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that lomustine had activity against MCTs in cats and was well tolerated. Further, findings suggested that treatment with lomustine should be considered for cats with MCTs for which local treatment is not an option.     

E-cadherin expression in canine cutaneous histiocytomas

Canine cutaneous histiocytoma is a common skin tumour of Langerhans cell origin. Langerhans cells are members of the dendritic cell family of antigen-presenting cells and are located in the epidermis. They are unique among the dendritic cell lineage in that they express high levels of the adhesion molecule E-cadherin. The expression of E-cadherin by the neoplastic Langerhans cells in 37 dogs with cutaneous histiocytoma was studied by flow cytometry and immunohistochemistry. In all the cases, these cells expressed E-cadherin, whereas the infiltrating lymphocytes did not.